Therapeutic strategies to target the CXCR-1/CXCR-2 axis or combination with immunotherapy have been proposed to improve antitumor efficacy in pancreatic cancer, metastatic melanoma, and metastatic colorectal carcinoma (35, 36). Here, CXCR2 is linked to pancreatic neoplasm.